MapLight Therapeutics (MPLT) announced completion of enrollment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. The company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluating ML-004 for the treatment of autism spectrum disorder. The Company expects to report topline results from both Phase 2 trials by mid-August.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MPLT:
- MapLight Therapeutics Announces Board Refresh and New Nominees
- MapLight Therapeutics initiated with a Buy at Needham
- Buy Rating on MapLight: Differentiated CNS Pipeline and Undervalued Schizophrenia Opportunity with Upside in Alzheimer’s and Neuropsychiatric Indications
- MapLight Therapeutics initiated with a Buy at TD Cowen
- MapLight Therapeutics Highlights Growing CNS Pipeline, Strong Cash Position